CASE economists have advised on a number of key European competition cases in the chemicals and pharmaceuticals industries. CASE combines expertise in competition economics with a solid understanding of the particular features of these industries including the implications of government regulation and intellectual property rights as well as the potential for innovation to rapidly change existing market structures.
Recent assignments include:
| • |
evaluation of state intervention in the assessment of
competition in generic drugs markets |
| • |
evaluation of competitive issues surround proprietary drug databases |
| • |
advice on the UCB/Schwarz Pharma merger |
| • |
advice to the plaintiffs in the European Commission infringement case against patent abuses |
| • |
assessment of damages in relation to the Vitamin cartel |
| • |
competitive assessment in contract litigation concerning bulk ethylene |
| • |
pre-merger advice in relation to a proposed acquisition of heavy chemicals firm |
| • |
Article 81 infringement in the paint distribution sector |
| |
|
| |
|
| |
|
|
